The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.

• Financial information

Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.

• Company strategy

Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

• See the current status of our pipeline

The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.

• Corporate reports

The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.

• Get more information on Idorsia stock

Andrew C. Weiss

Senior Vice President, Head of Investor Relations and Corporate Communications

• +41 58 844 10 10
• Contact us online